Literature DB >> 26639777

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.

Bruno Guy1, Nicholas Jackson1.   

Abstract

Dengue virus (DENV) is a human pathogen with a large impact on public health. Although no vaccine against DENV is currently licensed, a recombinant vaccine - chimeric yellow fever virus-DENV tetravalent dengue vaccine (CYD-TDV) - has shown efficacy against symptomatic dengue disease in two recent Phase III clinical trials. Safety observations were also recently reported for these trials. In this Opinion article, we review the data from recent vaccine clinical trials and discuss the putative mechanisms behind the observed efficacy of the vaccine against different forms of the disease, focusing on the interactions between the infecting virus, pre-existing host immunity and vaccine-induced immune responses.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26639777     DOI： 10.1038/nrmicro.2015.2

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN： 1740-1526            Impact factor:   60.633


  65 in total

1.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

2.  Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions.

Authors:  W C Blackwelder; J Storsaeter; P Olin; H O Hallander
Journal:  Am J Dis Child       Date:  1991-11

3.  CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.

Authors:  Raphaël M Zellweger; William W Tang; William E Eddy; Kevin King; Marisa C Sanchez; Sujan Shresta
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

4.  Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.

Authors:  Kizzmekia S Corbett; Leah Katzelnick; Hasitha Tissera; Ananda Amerasinghe; Aruna Dharshan de Silva; Aravinda M de Silva
Journal:  J Infect Dis       Date:  2014-10-21       Impact factor: 5.226

Review 5.  Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

6.  Virus-specific T lymphocytes home to the skin during natural dengue infection.

Authors:  Laura Rivino; Emmanuelle A Kumaran; Tun-Linn Thein; Chien Tei Too; Victor Chih Hao Gan; Brendon J Hanson; Annelies Wilder-Smith; Antonio Bertoletti; Nicholas R J Gascoigne; David Chien Lye; Yee Sin Leo; Arne N Akbar; David M Kemeny; Paul A MacAry
Journal:  Sci Transl Med       Date:  2015-03-11       Impact factor: 17.956

7.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

8.  Reduced risk of disease during postsecondary dengue virus infections.

Authors:  Sandra Olkowski; Brett M Forshey; Amy C Morrison; Claudio Rocha; Stalin Vilcarromero; Eric S Halsey; Tadeusz J Kochel; Thomas W Scott; Steven T Stoddard
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226

9.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

10.  An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.

Authors:  Stefan Fernandez; Stephen J Thomas; Rafael De La Barrera; Rawiwan Im-Erbsin; Richard G Jarman; Benoît Baras; Jean-François Toussaint; Sally Mossman; Bruce L Innis; Alexander Schmidt; Marie-Pierre Malice; Pascale Festraets; Lucile Warter; J Robert Putnak; Kenneth H Eckels
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345
View more
  73 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 2.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 3.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

Authors:  Stephen S Whitehead; Kanta Subbarao
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

4.  Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.

Authors:  Justin M Richner; Brett W Jagger; Chao Shan; Camila R Fontes; Kimberly A Dowd; Bin Cao; Sunny Himansu; Elizabeth A Caine; Bruno T D Nunes; Daniele B A Medeiros; Antonio E Muruato; Bryant M Foreman; Huanle Luo; Tian Wang; Alan D Barrett; Scott C Weaver; Pedro F C Vasconcelos; Shannan L Rossi; Giuseppe Ciaramella; Indira U Mysorekar; Theodore C Pierson; Pei-Yong Shi; Michael S Diamond
Journal:  Cell       Date:  2017-07-13       Impact factor: 41.582

5.  Insights from direct studies on human dengue infections.

Authors:  Scott B Halstead
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-13       Impact factor: 11.205

Review 6.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.

Authors:  Bruno Guy
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 7.  Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

Authors:  Anna P Durbin
Journal:  Curr Opin Virol       Date:  2020-10-23       Impact factor: 7.090

8.  Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

Authors:  Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

Review 9.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

Review 10.  Zika Virus: Immunity and Vaccine Development.

Authors:  Theodore C Pierson; Barney S Graham
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.